AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

Core Viewpoint - AbbVie is investing $195 million to expand its active pharmaceutical ingredient (API) production in North Chicago, Illinois, as part of a broader commitment to invest over $10 billion in the U.S. over the next decade [1][8]. Group 1: Investment and Expansion - The new API facility will enhance AbbVie's chemical synthesis capabilities in the U.S., supporting the production of current and next-generation medicines in neuroscience, immunology, and oncology [2][8]. - Construction of the new facility is set to begin in fall 2025, with full operational status expected by 2027 [3][8]. - This investment is part of AbbVie's long-term commitment to Illinois, where the company employs over 11,000 individuals [4][5]. Group 2: Economic Impact - The expansion will support more than 6,000 American jobs across 11 manufacturing sites and create additional jobs at suppliers throughout the U.S. [3][8]. - The investment is seen as a reinforcement of Illinois' biomanufacturing ecosystem and is expected to bolster the state's workforce and infrastructure [5]. Group 3: Strategic Importance - AbbVie's CEO emphasized that this expansion is crucial for maintaining U.S. leadership in pharmaceutical innovation and delivering impactful next-generation medicines [3]. - The investment aligns with AbbVie's mission to address serious health issues and medical challenges across key therapeutic areas [6].